Evaluation of Dermatological and Neurological Aspects of the Relationship Between Rosacea and Headaches

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Jan 11

PMID 38201332

Authors

Merve Alizada

Turgut Sahin

Ozden Sener

Pelin Kocyigit

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the relationship between rosacea and headaches, focusing on different subtypes, as well as the associated clinical features and triggering factors. In this prospective study, 300 patients diagnosed with rosacea and 320 control subjects without rosacea or any connected mast cell activation illness were included. Patients with rosacea were assessed by a dermatologist according to the 2019 updated rosacea classification (ROSCO panel). Accordingly, patients were classified based on their predominant rosacea subtype as follows: erythematotelangiectatic (ETR), papulopustular (PPR), or phymatous (RhR). Patients experiencing headaches were assessed using the International Headache Classification. Headaches were categorized as migraine, tension-type headaches (TTHs), secondary types (STHs), and cluster-type headaches (CTHs). The ratio of headache was 30.3% in the rosacea group, which did not show a significant difference compared to the control group (30.3% vs. 25.0%, = 0.138). In 81.3% of rosacea patients with headaches, headache onset occurred after the diagnosis of rosacea. The rate of patients with headaches was higher in the ETR group compared to the PPR and RhR groups (35.2% vs. 16.2% vs. 23.1%, = 0.007, respectively). In terms of headache subtypes, the rates of patients with migraine and STHs were higher in the ETR group compared to the PPR and RhR groups, while the rate of patients with TTHs was higher in the RhR group. A positive correlation was found between rosacea severity and migraine severity (r = 0.284, < 0.05). Among the triggering factors for rosacea, only sunlight was found to be associated with headaches. Lower age, female gender, and moderate to severe rosacea severity were identified as independent factors increasing the likelihood of headaches. A significant portion of rosacea patients experience headaches. Particularly, different subtypes of rosacea may be associated with various types of headaches. This study, highlighting the connection between migraine and ETR, is a pioneering work that demonstrates common pathogenic mechanisms and potential triggers.

References

Christensen C, Andersen F, Wienholtz N, Egeberg A, Thyssen J, Ashina M . The relationship between migraine and rosacea: Systematic review and meta-analysis. Cephalalgia. 2017; 38(7):1387-1398. DOI: 10.1177/0333102417731777. View

Matsuda M, Huh Y, Ji R . Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth. 2018; 33(1):131-139. PMC: 6813778. DOI: 10.1007/s00540-018-2579-4. View

Wienholtz N, Christensen C, Zhang D, Rechnagel A, Byrnel H, Haugaard J . Clinical characteristics of combined rosacea and migraine. Front Med (Lausanne). 2022; 9:1026447. PMC: 9635264. DOI: 10.3389/fmed.2022.1026447. View

Lundqvist C, Benth J, Grande R, Aaseth K, Russell M . A vertical VAS is a valid instrument for monitoring headache pain intensity. Cephalalgia. 2009; 29(10):1034-41. DOI: 10.1111/j.1468-2982.2008.01833.x. View

Spoendlin J, Voegel J, Jick S, Meier C . Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom. J Am Acad Dermatol. 2013; 69(3):399-406. DOI: 10.1016/j.jaad.2013.03.027. View

Sakabe J, Umayahara T, Hiroike M, Shimauchi T, Ito T, Tokura Y . Calcipotriol increases hCAP18 mRNA expression but inhibits extracellular LL37 peptide production in IL-17/IL-22-stimulated normal human epidermal keratinocytes. Acta Derm Venereol. 2014; 94(5):512-6. DOI: 10.2340/00015555-1775. View

Woo Y, Han Y, Kim H, Cho S, Lee J . Updates on the Risk of Neuropsychiatric and Gastrointestinal Comorbidities in Rosacea and Its Possible Relationship with the Gut-Brain-Skin Axis. Int J Mol Sci. 2020; 21(22). PMC: 7696644. DOI: 10.3390/ijms21228427. View

Stovner L, Hagen K, Linde M, Steiner T . The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022; 23(1):34. PMC: 9004186. DOI: 10.1186/s10194-022-01402-2. View

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

10.

Burch R, Buse D, Lipton R . Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019; 37(4):631-649. DOI: 10.1016/j.ncl.2019.06.001. View

11.

Schaller M, Almeida L, Bewley A, Cribier B, Del Rosso J, Dlova N . Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2019; 182(5):1269-1276. PMC: 7317217. DOI: 10.1111/bjd.18420. View

12.

Karsan N, Gosalia H, Goadsby P . Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides. Int J Mol Sci. 2023; 24(15). PMC: 10418996. DOI: 10.3390/ijms241511993. View

13.

Theoharides T, Donelan J, Kandere-Grzybowska K, Konstantinidou A . The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005; 49(1):65-76. DOI: 10.1016/j.brainresrev.2004.11.006. View

14.

Steel S, Robertson C, Whealy M . Current Understanding of the Pathophysiology and Approach to Tension-Type Headache. Curr Neurol Neurosci Rep. 2021; 21(10):56. DOI: 10.1007/s11910-021-01138-7. View

15.

Gerber P, Buhren B, Steinhoff M, Homey B . Rosacea: The cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011; 15(1):40-7. PMC: 3704141. DOI: 10.1038/jidsymp.2011.9. View

16.

Rainer B, Kang S, Chien A . Rosacea: Epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2018; 9(1):e1361574. PMC: 5821167. DOI: 10.1080/19381980.2017.1361574. View

17.

Lakhan S, Avramut M . Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets. Pain Res Treat. 2012; 2012:952906. PMC: 3434407. DOI: 10.1155/2012/952906. View

18.

Maniyar F, Sprenger T, Schankin C, Goadsby P . Photic hypersensitivity in the premonitory phase of migraine--a positron emission tomography study. Eur J Neurol. 2014; 21(9):1178-83. DOI: 10.1111/ene.12451. View

19.

Wienholtz N, Christensen C, Haugaard J, Zhang D, Ashina M, Thyssen J . Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open. 2020; 10(8):e039445. PMC: 7440817. DOI: 10.1136/bmjopen-2020-039445. View

20.

Marmura M . Triggers, Protectors, and Predictors in Episodic Migraine. Curr Pain Headache Rep. 2018; 22(12):81. DOI: 10.1007/s11916-018-0734-0. View